Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | CA12 | O43570 | 4/20 | 0.56 |
| ▸ | CA1 | P00915 | 4/20 | 0.56 |
| ▸ | CA2 | P00918 | 4/20 | 0.56 |
| ▸ | CA7 | P43166 | 4/20 | 0.56 |
| ▸ | CA9 | Q16790 | 4/20 | 0.56 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | ESR1 | P03372 | 1/20 | 0.48 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29668381 | 1.00 | MEN1 (0.60) | MEN1KMT2ATSHRCA12CA1 | |
| SCHEMBL23817369 | 0.88 | MEN1 (0.53) | MEN1KMT2ATSHRCA12CA1 | |
| SCHEMBL9579673 | 0.87 | ALDH1A1 (0.58) | MEN1KMT2ATSHRCA12CA1 | |
| SCHEMBL25859075 | 0.87 | MEN1 (0.55) | MEN1KMT2ATSHRCA12CA1 | |
| SCHEMBL301748 | 0.86 | TSHR (0.64) | MEN1KMT2ATSHRCA12CA1 | |
| SCHEMBL9360728 | 0.85 | TSHR (0.64) | MEN1KMT2ATSHRCA12CA1 | |
| SCHEMBL15709794 | 0.85 | MEN1 (0.54) | MEN1KMT2ACA12CA1CA2 | |
| SCHEMBL9642581 | 0.85 | MEN1 (0.54) | MEN1KMT2ATSHRCA12CA1 | |
| SCHEMBL4484997 | 0.85 | MEN1 (0.54) | MEN1KMT2ACA12CA1CA2 | |
| SCHEMBL7041225 | 0.85 | KMT2A (0.54) | MEN1KMT2ATSHRCA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 298 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115895623-B | Asphaltene deposition inhibitor composition and preparation method and application thereof | 中国石油化工股份有限公司 | 2023-12-12 | — | — | CN | claimed |
| CN-115895623-A | Asphaltene deposition inhibitor composition, and preparation method and application thereof | 中国石油化工股份有限公司 | 2023-04-04 | — | — | CN | claimed |
| CN-112778442-A | Olefin polymerization catalyst solid component, preparation method thereof, olefin polymerization catalyst and application | 中国石油化工股份有限公司 | 2021-05-11 | — | — | CN | claimed |
| CN-112759683-A | Olefin polymerization catalyst and application | 中国石油化工股份有限公司 | 2021-05-07 | — | — | CN | claimed |
| EP-1581480-B1 | CYCLOPENTYL-SUBSTITUTED GLUTARAMIDE COMPOUNDS AS ENDOPEPTIDASE-V INHIBITORS | PFIZER LTD (GB) | 2006-08-23 | — | — | EP | claimed |
| US-7045653-B2 | cyclopentyl substituted glutaramide derivatives; inhibitors of neutral endopeptidase which may be used to treat cardiovascular disorders, especially hypertension | PFIZER, INC. (US) | 2006-05-16 | — | — | US | claimed |
| EP-1581480-A1 | CYCLOPENTIL-SUBSTITUTED GLUTARAMIDE COMPOUNDS AS ENDOPEPTIDASEV INHIBITORS | Pfizer Limited (GB) | 2005-10-05 | — | — | EP | claimed |
| EP-1578735-A1 | CYCLOPENTYL GLUTARAMIDES AND THEIR USE AS NEUTRAL ENDOPEPTIDASE INHIBITORS | Pfizer Limited (GB) | 2005-09-28 | — | — | EP | claimed |
| US-20050075392-A1 | Novel pharmaceuticals | DACK KEVIN NEIL (GB) | 2005-04-07 | — | — | US | claimed |
| US-20040138274-A1 | Cardiovascular disorders; hypotensive agents; endopeptidase inhibitor; sexual disorders | DACK KEVIN NEIL (GB) | 2004-07-15 | — | — | US | claimed |
| WO-2004056787-A1 | CYCLOPENTYL GLUTARAMIDES AND THEIR USE AS NEUTRAL ENDOPEPTIDASE INHIBITORS | PFIZER LIMITED (GB) | 2004-07-08 | — | — | WO | claimed |
| WO-2004056750-A1 | CYCLOPENTIL-SUBSTITUTED GLUTARAMIDE COMPOUNDS AS ENDOPEPTIDASE INHIBITORS | PFIZER LIMITED (GB) | 2004-07-08 | — | — | WO | claimed |
| EP-0342850-B1 | ENANTIOMERIC GLUTARAMIDE DIURETIC AGENTS | Pfizer Limited (GB) | 1992-05-20 | — | — | EP | claimed |
| EP-0274234-B1 | SPIRO-SUBSITUTED GLUTARAMIDE DIURETIC AGENTS | Pfizer Limited (GB) | 1991-09-11 | — | — | EP | claimed |
| WO-1991010644-A1 | CYCLOALKYL-SUBSTITUTED GLUTARAMIDE DIURETIC AGENTS | PFIZER LIMITED (GB) | 1991-07-25 | — | — | WO | claimed |
| US-5030654-A | Glutaramide diuretic agents | PFIZER INC. (US) | 1991-07-09 | — | — | US | claimed |
| WO-1991007378-A1 | CYCLOALKYL-SUBSTITUTED GLUTARAMIDE DIURETIC AGENTS | PFIZER LIMITED (GB) | 1991-05-30 | — | — | WO | claimed |
| EP-0342850-A1 | Enantiomeric glutaramide diuretic agents | Pfizer Limited (GB) | 1989-11-23 | — | — | EP | claimed |
| EP-3419051-B1 | CURABLE RESIN COMPOSITION AND FAN OUT TYPE WAFER LEVEL PACKAGE | TAIYO HOLDINGS CO LTD (JP) | 2026-04-08 | — | — | EP | disclosed |
| EP-0274234-A2 | Spiro-subsituted glutaramide diuretic agents | Pfizer Limited (GB) | 1988-07-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075392-A1 | Novel pharmaceuticals | MME, ECE1, ECE2 | MEN1 2639/4885KMT2A 3712/4885TSHR 1753/4885 |
| US-20040138274-A1 | Cardiovascular disorders; hypotensive agents; endopeptidase inhibitor; sexual disorders | MME, ECE1, ECE2 | MEN1 2225/4885KMT2A 3724/4885TSHR 3192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.